cervical cancer

Cervical cancer screening is an essential tool for reduction of associated incidence and mortality. Currently, high-risk Human Papilloma Virus (hr-HPV) testing is the first line of cervical cancer screening. This method is highly sensitive but with limited specificity. Thus, the research teams from IPOPorto and Administração Regional de Saúde do Norte tested DNA methylation-based biomarkers in formalin-fixed paraffin embedding samples and cervical smears for triage of women positive for hr-HPV.

The team led by Ângela Sousa from Health Science Research Centre of the University of Beira Interior (CICS-UBI) has been focused on the development of biotechnological strategies with therapeutic potential for cervical cancer treatment. Cervical cancer is the fourth most diagnosed cancer in women, with an estimated 570 000 new cases and representing 6.6% of all female cancers in 2018 worldwide.

A equipa liderada por Ângela Sousa, do Centro de Investigação em Ciências da Saúde da Universidade da Beira Interior (CICS-UBI), tem-se focado no desenvolvimento de estratégias biotecnológicas com potencial terapêutico para o tratamento do cancro do colo do útero. O cancro do colo do útero é o quarto cancro mais frequentemente diagnosticado em mulheres, com uma estimativa de 570.000 novos casos e representando 6,6% dos casos totais de cancros femininos em todo o mundo em 2018.

In the last years, the research team of Ângela Sousa has been focused on the development of biotechnological strategies with therapeutic potential for cervical cancer treatment. The development of this disease is strongly associated with infection by Human Papillomavirus (HPV), being the latter responsible for the production of E6 and E7 oncoproteins. These proteins have the ability of interfering with cellular regulatory mechanisms fueled by tumor suppressor proteins, such as p53 and pRB proteins.

Nos últimos anos, a equipa de investigação de Ângela Sousa tem-se focado no desenvolvimento de estratégias biotecnológicas com potencial terapêutico no tratamento de cancro do colo do útero. O desenvolvimento desta doença está fortemente associado à infeção pelo Vírus do Papiloma Humano (HPV), sendo que este último é responsável pela produção das oncoproteínas E6 e E7.

Finding a New Viral Cause of Cervical Cancer—Virtually all cases of cervical cancer are caused by high-risk types of human papillomavirus (HPV). In a study published online on April 9 in International Journal of Cancer, Ana Gradissimo, Ph.D., and Robert D. Burk, M.D., provide the first molecular evidence showing that HPV73—now classified as “possibly oncogenic”—definitely can cause cervical cancer.

Cape Town, South Africa

28 February - 04 March 2017
 

See more informations here: http://www.hpv2017.org/

Cape Town, South Africa

28 February - 04 March 2017
 

See more informations here: http://www.hpv2017.org/

Authors and Affiliations: